↓ Skip to main content

Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer

Overview of attention for article published in Investigational New Drugs, March 2010
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (64th percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

policy
1 policy source

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
23 Mendeley
Title
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer
Published in
Investigational New Drugs, March 2010
DOI 10.1007/s10637-010-9413-7
Pubmed ID
Authors

Colin D. Weekes, Sujatha Nallapareddy, Michelle A. Rudek, Alexis Norris-Kirby, Daniel Laheru, Antonio Jimeno, Ross C. Donehower, Kathleen M. Murphy, Manuel Hidalgo, Sharyn D. Baker, Wells A. Messersmith

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 4%
Unknown 22 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 26%
Professor > Associate Professor 4 17%
Unspecified 3 13%
Student > Doctoral Student 3 13%
Student > Master 2 9%
Other 5 22%
Readers by discipline Count As %
Medicine and Dentistry 7 30%
Unspecified 4 17%
Agricultural and Biological Sciences 3 13%
Nursing and Health Professions 2 9%
Biochemistry, Genetics and Molecular Biology 2 9%
Other 5 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2017.
All research outputs
#2,603,923
of 9,679,413 outputs
Outputs from Investigational New Drugs
#64
of 430 outputs
Outputs of similar age
#90,330
of 261,740 outputs
Outputs of similar age from Investigational New Drugs
#2
of 12 outputs
Altmetric has tracked 9,679,413 research outputs across all sources so far. This one has received more attention than most of these and is in the 57th percentile.
So far Altmetric has tracked 430 research outputs from this source. They receive a mean Attention Score of 4.7. This one has gotten more attention than average, scoring higher than 54% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 261,740 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.